This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kesmodel, S. Articles by Fraker, D. Search for Related Content PubMed PubMed Citation Articles by Kesmodel, S. Articles by Fraker, D. Related Collections Thyroid Endocrine Oncology

Virus-Mediated Oncolysis of Thyroid Cancer by a Replication-Selective Adenovirus Driven by a Thyroglobulin Promoter-Enhancer Region

Division of Endocrine and Oncologic Surgery, Department of Surgery (S.K., I.P., R.C., C.M., D.F.), and Department of Pathology (K.M.-K.), University of Pennsylvania, Philadelphia, Pennsylvania 19104

Address all correspondence and requests for reprints to: Dr. Douglas Fraker, Division of Endocrine and Oncologic Surgery, HUP, 4 Silverstein Building, 3400 Spruce Street, Philadelphia, Pennsylvania 19104. E-mail: frakerd{at}uphs.upenn.edu.

Context: Currently, there is no effective treatment for iodine-resistant thyroid cancers.

Objective: As a new approach to treatment, the efficacy of replication-selective, human thyroglobulin (TG) enhancer and promoter-driven, adenovirus (AdhTGEP)-mediated oncolysis was investigated using two well-differentiated thyroid cancer cell lines, XTC (TG positive) and FTC-133 (TG negative), and other control tumor and nontumor cell lines (all TG negative).

Design: A cohort study design was used.

Setting: The study setting was laboratory bench-top experiments.

Subjects/Participants: In vitro TG-expressing and nonexpressing thyroid cell culture lines, nonthyroid tumor cell lines, as well as preclinical thyroid tumor-bearing mice were studied.

Intervention: Adenoviral infection of cell lines was determined by immunohistochemistry, selective replication by one-step growth assays, and cytotoxicity by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrozolium (MTS) assay. In vivo tumor growth inhibition was determined by a single intratumoral injection of 1 x 10⁹ plaque-forming units AdhTGEP, AdLacZ (control virus), or PBS to 50- to 75-mm³ tumors. XTC cells showed intense immunohistochemical staining, whereas FTC-133 and all other control cell lines showed minimal staining for viral infection with AdhTGEP.

Main Outcome Measures: Cell survival and tumor growth inhibition after adenoviral infection were the main outcome measures.

Results: One-step growth assays showed at least a more than 60-fold titer of AdhTGEP in XTC than in FTC-133 cells. Cytotoxicity assays showed approximately 68% cell kill in XTC and minimal cell kill in FTC-133 and all other control cell lines at a multiplicity of infection of 250. There was significant in vivo growth inhibition of AdhTGEP-treated XTC tumors (67 ± 49 mm³) compared with AdLacZ-treated XTC (228 ± 45 mm³; P < 0.01), PBS-treated XTC (372 ± 70 mm³; P < 0.001), or AdhTGEP-treated FTC-133 tumors (598 ± 168 mm³).

Conclusion: Replication-selective virus-mediated oncolysis is a potential therapy for recurrent, well-differentiated, TG-secreting thyroid cancer that is unresponsive to standard treatment.

This article has been cited by other articles:

				A. S. Rao, P. E. Goretzki, J. Kohrle, and G. Brabant Letter re: Id1 Gene Expression in Hyperplastic and Neoplastic Thyroid Tissues J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5906 - 5906. [Full Text] [PDF]